Polaris AI Pharma Accelerates Overseas Expansion, Supplies to Government Procurement Markets in Russia, Saudi Arabia, and Mexico

Polaris AI Pharma, a company specializing in active pharmaceutical ingredients (APIs), announced on the 24th that it is expanding its global presence by entering overseas government procurement markets in countries such as Russia, Saudi Arabia, and Mexico, in addition to its domestic market.

Following its entry into the Chinese market, the company is now leveraging its achievements in emerging markets to diversify its global supply chain and enhance profitability.

Polaris AI Pharma is an API manufacturing specialist with export capabilities to Japan, Central and South America, Southeast Asia, and Europe. Unlike most domestic API companies, it has focused on overseas market development from an early stage rather than remaining solely in the domestic market. In particular, it has supplied various APIs, including Droxidopa, to Japanese pharmaceutical companies for many years, earning a reputation for quality and reliability.

Although overseas sales temporarily slowed during the COVID-19 pandemic, they have recently begun to recover. In fact, Polaris AI Pharma has completed registration of its API for Roxatidine Acetate Hydrochloride, a treatment for gastric and duodenal ulcers, with the National Medical Products Administration (NMPA) in China and has successfully commercialized it, establishing a foothold in the Chinese market.

Subsequently, the company has won consecutive government bids in Russia and Mexico through local clients and has also signed new contracts in Saudi Arabia, solidifying its entry into key emerging markets.

A company representative stated, "Achieving results in overseas export markets, which demand both strict quality standards and price competitiveness, demonstrates that Polaris AI Pharma's product capabilities are proven on the international stage. Our highly profitable global expansion strategy is delivering results."

As diversification of supply chains becomes more prevalent in the global pharmaceutical industry, Polaris AI Pharma's multi-regional expansion is also drawing attention. Building on its foundation in the Asian market, the company is broadening its business scope into Russia, the Middle East, and Central and South America, further strengthening its position in the global pharmaceutical supply chain.

A Polaris AI Pharma official commented, "Our key differentiator is building supply chains in a variety of regions rather than relying on a single country or client. Next year, we plan to continue our growth not only through government procurement markets but also by collaborating with private pharmaceutical companies."

The official added, "In addition to our core API business, we plan to expand our contract development and manufacturing organization (CDMO) operations and actively foster new businesses that incorporate AI."

Meanwhile, Polaris AI Pharma is stably operating its generic-based API and CDMO businesses. Since joining the Polaris Group, the company has also been working to expand into AI-based pharmaceutical R&D data businesses in collaboration with Polaris Office, focusing on software-driven solutions.

This content was produced with the assistance of AI translation services.